Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple app help pharmacists stop HIV?

NCT ID NCT07683117

Disease control Sponsor: EMPOWERX INC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tests whether a software program called PEPPI makes it easier for pharmacists to offer HIV prevention pills (PEP and PrEP) and for patients to get them. Pharmacists and patients use the software during their normal visits, and researchers compare how well the service works with and without the tool. The goal is to see if technology can boost access to HIV prevention in community pharmacies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PEPPI software (digital tool for pharmacist-prescribed HIV prevention)
What this could lead to
If it works, this software could make HIV prevention pills more accessible by letting pharmacists prescribe them more easily.
What could go wrong
This is a small implementation study, not a test of the drugs themselves. The software may not improve access or be adopted widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 195 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PHARMACIST Participants Inclusion Criteria: * 18 years of age or older * Provide, or willing to provide, PEP/PrEP services in a participating pharmacy * Use the PEPPI software to provide birth control services Exclusion Criteria: * None PATIENT Participants Inclusion Criteria: * 18 years of age or older * Seek PEP or PrEP services at a participating pharmacy * Use the PEPPI software to receive PEP/PrEP services at a participating pharmacy Exclusion Criteria: * NONE

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Access and linkage to healthcare are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Access and linkage to healthcare HIV pre-exposure prophylaxis HIV prevention Technology use

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • EmpoweRx, Inc

    RECRUITING

    Del Mar, California, 92014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.